Report: New Laws Needed to Control Prices of HIV and Hepatitis Drugs
December 30, 2016
According to FPC member Sean Dickson, lead author of the report and senior manager of Health Systems Integration for the National Alliance of State and Territorial AIDS Directors (NASTAD), statutes currently in place have failed to prevent skyrocketing drug prices, and lifesaving HIV and hepatitis C drugs and biologics are among those with more egregious pricing. The report, which was distributed to the president-elect's transition team and to congressional leaders, includes step-by-step procedures that can be implemented quickly as bipartisan support grows for measures to control escalating drug costs.
The FPC analysis shows that modernizing statutes and strengthening the system's existing framework can reduce federal drug spending and help eliminate unacceptable price increases for medicines and biologics in the private sector. They say much of the problem stems from this central issue: Although cost control measures are already in place through existing statutes, federal legislation has not kept up with tactics used by pharmaceutical companies and drug manufacturers to sidestep these regulations.
In the report, the FTC presents the following four pathways, which expand on existing statutes and provide specific legislative actions:
Diane Domina is a senior content producer at Remedy Health Media, LLC. She writes the Daily Dose for HealthCentral and is the editorial director at HealthCommunities. Her goal is to contribute to a valuable, trustworthy and informative experience for people who are searching for health information online.
The Fair Pricing Coalition Releases New Report Urging Modernization of Existing Laws to Rein in Drug Pricing
This article was provided by TheBody.
Add Your Comment:
(Please note: Your name and comment will be public, and may even show up in
Internet search results. Be careful when providing personal information! Before
adding your comment, please read TheBody.com's Comment Policy.)